Adaptive Pathways: A Solution For Worried Payers in Europe

 
• By Neena Brizmohun

Payers often worry about where they would stand if a drug that was approved in the context of adaptive pathways should subsequently underperform. But they should not be concerned, according to the latest discussions on this relatively new concept for getting drugs to market faster.

airport runway under the sun as background
Adaptive pathways is seeking to get drugs for high unmet medical needs to patients faster

More from Market Access

More from Pink Sheet